Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GILEAD SCIENCES, INC.GILD · Entity 405 | Director · Chairman & CEO | October 01, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GILEAD SCIENCES, INC.
Report date October 01, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 566,683 |
Ending reported balance
After 2026-10-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-01 · Sale · Disposed 12,000 · Balance 569,683 F1: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026. F2: Sale prices for the transactions reported range from $147.21 to $148.205. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Row 2 · 2026-10-01 · Sale · Disposed 3,000 · Balance 566,683 F1: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026. F3: Sale prices for the transactions reported range from $148.23 to $149.13. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026.
F2: Sale prices for the transactions reported range from $147.21 to $148.205. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
F3: Sale prices for the transactions reported range from $148.23 to $149.13. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 10, 2023 Filed Mar 14, 2023 16:03 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 215,095 | $0.00 Strike: $79.50 | $0.00 |
DisclosureSEC source: 0001127602-23-010012 · form4.xml · derivative · entry 7 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,095 Underlying: Common Stock · 215,095 shares Expires 2033-03-10 F4 · derivative.exercise_date: The shares subject to the option have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 16:03 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Unit · Derivative | 47,170 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-010012 · form4.xml · derivative · entry 6 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,933 Underlying: Common Stock · 47,170 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 16:03 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 10,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-010012 · form4.xml · derivative · entry 5 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,763 Underlying: Common Stock · 10,800 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. F3 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 16:03 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 19,488 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-010012 · form4.xml · derivative · entry 4 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,563 Underlying: Common Stock · 19,488 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 16:03 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 14,017 | $79.50 | $1,114,351.50 |
DisclosureSEC source: 0001127602-23-010012 · form4.xml · nonDerivative · entry 3 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,766 Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 16:03 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 10,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-010012 · form4.xml · nonDerivative · entry 2 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 389,783 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 16:03 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 19,488 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-010012 · form4.xml · nonDerivative · entry 1 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 378,983 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 23:48 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 11,362 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-008485 · form4.xml · derivative · entry 3 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,051 Underlying: Common Stock · 11,362 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 23:48 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 4,842 | $79.59 | $385,374.78 |
DisclosureSEC source: 0001127602-23-008485 · form4.xml · nonDerivative · entry 2 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 359,495 Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 23:48 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 11,362 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-008485 · form4.xml · nonDerivative · entry 1 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 364,337 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| January 24, 2023 Filed Jan 26, 2023 20:44 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 59,078 | $84.02 | $4,963,733.56 |
DisclosureSEC source: 0001127602-23-002288 · form4.xml · nonDerivative · entry 3 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 352,975 Read SEC document |
| January 24, 2023 Filed Jan 26, 2023 20:44 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 136,647 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-002288 · form4.xml · nonDerivative · entry 2 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 412,053 F2 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on March 10, 2020. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors Read SEC document |
| January 24, 2023 Filed Jan 26, 2023 20:44 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 78,370 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-002288 · form4.xml · nonDerivative · entry 1 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,406 F1 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on March 10, 2021 and March 10, 2022. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until the requisite continuing service requirements are also met. Read SEC document |
| December 10, 2022 Filed Dec 13, 2022 20:13 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 3,300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-027388 · form4.xml · derivative · entry 3 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,413 Underlying: Common Stock · 3,300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| December 10, 2022 Filed Dec 13, 2022 20:13 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 1,542 | $87.97 | $135,649.74 |
DisclosureSEC source: 0001127602-22-027388 · form4.xml · nonDerivative · entry 2 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,636 Read SEC document |
| December 10, 2022 Filed Dec 13, 2022 20:13 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 3,300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-027388 · form4.xml · nonDerivative · entry 1 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,178 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| September 10, 2022 Filed Sep 12, 2022 20:06 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 3,301 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-022291 · form4.xml · derivative · entry 3 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,713 Underlying: Common Stock · 3,301 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| September 10, 2022 Filed Sep 12, 2022 20:06 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 1,528 | $65.28 | $99,747.84 |
DisclosureSEC source: 0001127602-22-022291 · form4.xml · nonDerivative · entry 2 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,878 Read SEC document |
| September 10, 2022 Filed Sep 12, 2022 20:06 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 3,301 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-022291 · form4.xml · nonDerivative · entry 1 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,406 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| June 10, 2022 Filed Jun 13, 2022 23:59 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 3,300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-017325 · form4.xml · derivative · entry 3 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,014 Underlying: Common Stock · 3,300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| June 10, 2022 Filed Jun 13, 2022 23:59 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 1,539 | $60.74 | $93,478.86 |
DisclosureSEC source: 0001127602-22-017325 · form4.xml · nonDerivative · entry 2 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,105 Read SEC document |
| June 10, 2022 Filed Jun 13, 2022 23:59 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 3,300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-017325 · form4.xml · nonDerivative · entry 1 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,644 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:52 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Unit · Derivative | 64,745 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-009217 · form4.xml · derivative · entry 7 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,314 Underlying: Common Stock · 64,745 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F3 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:52 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 399,235 | $0.00 Strike: $57.92 | $0.00 |
DisclosureSEC source: 0001127602-22-009217 · form4.xml · derivative · entry 6 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 399,235 Underlying: Common Stock · 399,235 shares Expires 2032-03-10 F4 · derivative.exercise_date: The shares subject to the option have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:52 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 13,203 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-009217 · form4.xml · derivative · entry 5 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,569 Underlying: Common Stock · 13,203 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F3 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:52 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 10,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-009217 · form4.xml · derivative · entry 4 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,772 Underlying: Common Stock · 10,800 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:52 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 11,052 | $57.92 | $640,131.84 |
DisclosureSEC source: 0001127602-22-009217 · form4.xml · nonDerivative · entry 3 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,344 Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:52 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 13,203 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-009217 · form4.xml · nonDerivative · entry 2 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,396 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| March 10, 2022 Filed Mar 15, 2022 01:52 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 10,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-009217 · form4.xml · nonDerivative · entry 1 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,193 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 00:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 42,922 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-008127 · form4.xml · derivative · entry 5 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,572 Underlying: Common Stock · 42,922 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: The restricted stock units have a three year vesting schedule. 1/3 vest on each yearly anniversary of the date of grant until fully vested. F3 · derivative.expiration_date: The restricted stock units have a three year vesting schedule. 1/3 vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 00:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 11,362 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-008127 · form4.xml · derivative · entry 4 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,494 Underlying: Common Stock · 11,362 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 00:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 23,245 | $60.26 | $1,400,743.70 |
DisclosureSEC source: 0001127602-22-008127 · form4.xml · nonDerivative · entry 3 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,393 Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 00:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 42,922 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-008127 · form4.xml · nonDerivative · entry 2 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,638 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 00:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 11,362 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-008127 · form4.xml · nonDerivative · entry 1 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,716 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| January 26, 2022 Filed Jan 29, 2022 01:52 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 33,833 | $67.34 | $2,278,314.22 |
DisclosureSEC source: 0001127602-22-002466 · form4.xml · nonDerivative · entry 3 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,354 Read SEC document |
| January 26, 2022 Filed Jan 29, 2022 01:52 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 82,670 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-002466 · form4.xml · nonDerivative · entry 2 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,187 F2 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on February 6, 2019. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors. Read SEC document |
| January 26, 2022 Filed Jan 29, 2022 01:52 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 64,008 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-002466 · form4.xml · nonDerivative · entry 1 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,517 F1 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on March 10, 2020, and March 10, 2021. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until the requisite continuing service requirements are also met. Read SEC document |
| March 10, 2021 Filed Mar 13, 2021 02:59 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 10,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-010492 · form4.xml · derivative · entry 5 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,856 Underlying: Common Stock · 10,800 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2021 Filed Mar 13, 2021 02:59 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 307,355 | $63.91 Strike: $63.91 | $19,643,058.05 |
DisclosureSEC source: 0001127602-21-010492 · form4.xml · derivative · entry 4 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,355 Underlying: Common Stock · 307,355 shares Expires 2021-03-12 F4 · price: The options have a four-year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F3 · derivative.exercise_date: The shares subject to the option have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2021 Filed Mar 13, 2021 02:59 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Unit · Derivative | 52,810 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-010492 · form4.xml · derivative · entry 3 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,656 Underlying: Common Stock · 52,810 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2021 Filed Mar 13, 2021 02:59 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 5,123 | $63.91 | $327,410.93 |
DisclosureSEC source: 0001127602-21-010492 · form4.xml · nonDerivative · entry 2 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,013 Read SEC document |
| March 10, 2021 Filed Mar 13, 2021 02:59 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 10,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-010492 · form4.xml · nonDerivative · entry 1 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,136 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| March 10, 2021 Filed Mar 31, 2021 22:53 UTC Amendment | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 10,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-012438 · form4a.xml · derivative · entry 5 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,856 Underlying: Common Stock · 10,800 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F4 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. F4 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| March 10, 2021 Filed Mar 31, 2021 22:53 UTC Amendment | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 307,355 | $0.00 Strike: $63.91 | $0.00 |
DisclosureSEC source: 0001127602-21-012438 · form4a.xml · derivative · entry 4 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,355 Underlying: Common Stock · 307,355 shares Expires 2031-03-10 F3 · derivative.exercise_date: The shares subject to the option have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2021 Filed Mar 31, 2021 22:53 UTC Amendment | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Unit · Derivative | 52,810 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-012438 · form4a.xml · derivative · entry 3 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,656 Underlying: Common Stock · 52,810 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2021 Filed Mar 31, 2021 22:53 UTC Amendment | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 5,123 | $63.91 | $327,410.93 |
DisclosureSEC source: 0001127602-21-012438 · form4a.xml · nonDerivative · entry 2 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,013 Read SEC document |
| March 10, 2021 Filed Mar 31, 2021 22:53 UTC Amendment | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 10,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-012438 · form4a.xml · nonDerivative · entry 1 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,136 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 18:46 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 11,363 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-009014 · form4.xml · derivative · entry 5 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,846 Underlying: Common Stock · 11,363 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. F3 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 18:46 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 42,923 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-009014 · form4.xml · derivative · entry 4 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,209 Underlying: Common Stock · 42,923 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a three year vesting schedule. 1/3 vest on each yearly anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a three year vesting schedule. 1/3 vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 18:46 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 24,620 | $62.46 | $1,537,765.20 |
DisclosureSEC source: 0001127602-21-009014 · form4.xml · nonDerivative · entry 3 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,336 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.